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Abstract Thrombophilias are hereditary and/or acquired
conditions that predispose patients to thrombosis. Testing
for thrombophilia is commonly performed in patients with
venous thrombosis and their relatives; however such testing
usually does not provide information that impacts man-
agement and may result in harm. This manuscript, initiated
by the Anticoagulation Forum, provides clinical guidance
for thrombophilia testing in five clinical situations: fol-
lowing 1) provoked venous thromboembolism, 2) unpro-
voked venous thromboembolism; 3) in relatives of patients
with thrombosis, 4) in female relatives of patients with
thrombosis considering estrogen use; and 5) in female
relatives of patients with thrombosis who are considering
pregnancy. Additionally, guidance is provided regarding
the timing of thrombophilia testing. The role of
thrombophilia testing in arterial thrombosis and for eval-
uation of recurrent pregnancy loss is not addressed. State-
ments are based on existing guidelines and consensus
expert opinion where guidelines are lacking. We recom-
mend that thrombophilia testing not be performed in most
situations. When performed, it should be used in a highly
selective manner, and only in circumstances where the
information obtained will influence a decision important to
the patient, and outweigh the potential risks of testing.
Testing should not be performed during acute thrombosis
or during the initial (3-month) period of anticoagulation.
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Introduction
Thrombophilias are hereditary or acquired conditions
which can increase the risk of venous or arterial throm-
bosis. As the etiology of thrombosis is multifactorial, the
presence of a thrombophilic defect is only one of many
elements that determine risk. Therefore, the utility of
testing for thrombophilia to inform prevention and treat-
ment decisions is controversial. In this guidance document,
we will review evidence and provide guidance regarding
thrombophilia testing to inform clinical decisions regarding
duration of anticoagulation following venous thromboem-
bolism (VTE) and primary prevention of VTE in relatives
of affected patients. Testing for thrombophilia in the con-
text of arterial thrombosis, and recurrent pregnancy loss is
not addressed. As no randomized, prospective trials have
tested the utility of testing for thrombophilia, evidence is
taken from epidemiologic studies.
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Background
Hereditary thrombophilias
The term ‘‘hereditary’’ or ‘‘inherited’’ thrombophilia has
most commonly been applied to conditions in which a
genetic mutation affects the amount or function of a protein
in the coagulation system. Loss of function mutations
include those affecting antithrombin (AT), protein C (PC)
and protein S (PS) [1–3]. Gain of function mutations
include the factor V Leiden (FVL) and the prothrombin
gene 20210 A/G (PGM) mutations [4, 5]. Testing for these
defects will be addressed in this guidance statement. We
will not address other conditions, such as abnormal levels
of other coagulation proteins (e.g., elevated factor VIII
levels) elevated homocysteine, or abnormalities of fibri-
nolytic proteins. Over time it is likely that more defects
will be identified [6]. This guidance statement also does not
address hereditary factors not assessed in the laboratory,
such as gender, height, leg length, and body mass index;
which also affect thrombosis risk [7–10].
Acquired thrombophilias
The antiphospholipid syndrome (APS) is the sine qua non
example of an acquired thrombophilia, and guidance
statements address testing for this condition. While not
specifically addressed herein, many other acquired condi-
tions can increase the risk of thrombosis, such as acquired
abnormalities in coagulation proteins (e.g. deficiencies in
the natural anticoagulants, activated protein C resistance in
the absence of FVL) and certain diseases (e.g. myelopro-
liferative neoplasms, paroxysmal nocturnal hemoglobin-
uria, cancer). Some medications increase thrombosis risk,
including exogenous hormones and chemotherapy [11].
Acquired characteristics such as smoking, obesity,
increasing age and pregnancy also increase risk [11].
Strong vs. weak thrombophilias
Some authors have classified thrombophilias as ‘‘strong’’ or
‘‘weak’’ based on the magnitude of thrombosis risk con-
ferred. It should be noted that published VTE guidelines
differ in these classifications [12–14] and that uncertainty
exists because of the broad confidence intervals around risk
estimates for the more rare thrombophilias [15–18]. The
risk of thrombosis conferred by a given thrombophilia may
vary by circumstance (e.g. in pregnancy) [19–24].
Depending on the classification system, it may not be
possible to identify instances of strong thrombophilia
without also identifying the more common weak cases. For
example, based on the high prevalence of FVL, as many as
128 heterozygotes (considered a weak thrombophilia)
would be found for every homozygote.
Thrombophilia testing
Testing for thrombophilias should only be performed when
results will be used to improve or modify management.
Testing has been suggested to assist with secondary pre-
vention (determining the duration of anticoagulation fol-
lowing a thrombotic event); and for hereditary disorders, to
aid in primary prevention in relatives of affected patients.
Guidance statements herein are based on analysis of the
utility and disutility of positive or negative test results to
inform these decisions. Disutility primarily results from a
decision to withhold anticoagulants from patients at high
risk for thrombosis (placing them at risk of a thrombotic
event); or providing anticoagulants to patients at low risk
of thrombosis (placing them at risk for bleeding). Other
potential types of disutility include cost, spurious results
due to inappropriate timing of testing [25], misinterpreta-
tion of results (by patients or healthcare providers) [26–28],
emotional distress and anxiety [28, 29], and the possibility
of genetic discrimination [30]. Potential utilities include
patient satisfaction from having identification of a biologic
risk factor underlying a thrombotic event, and an increased
likelihood of using prophylaxis in high risk situations by
affected relatives [31, 32]. The presence of hereditary
thrombophilia does not affect survival in patients with a
history of VTE [33] or the risk of post-thrombotic syn-
drome [34].
Methods
We chose to address five questions relevant to throm-
bophilia testing to inform clinical decisions regarding pri-
mary and secondary prevention for VTE, and one question
regarding the timing of testing. A literature search of
MEDLINE from January 1990 to July 2015 was conducted,
restricted to publications in English. The following search
terms were used and combined: lupus anticoagulant,
antiphospholipid, antithrombin, protein S, protein C, pro-
thrombin gene mutation, activated protein C resistance,
prothrombin G20210A, factor V Leiden, thrombophilia,
pulmonary embolism, venous thrombosis, deep vein
thrombosis, venous thromboembolism, primary prevention,
secondary prevention. When meta-analyses, reviews or
guideline articles were identified, the reference lists of
these were reviewed for additional citations of interest. We
preferred prospective cohort studies to inform guidance
statements when available, but guidance could also derive
from case–control and retrospective studies. Table 1 sum-
marizes the guidance questions in this chapter.
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Guidance
Secondary prevention following provoked VTE
(1) Should thrombophilia testing be performed to help
determine duration of anticoagulation following
provoked VTE?
Of the many factors which predict the risk of recurrent
thrombosis after an initial event, the presence of provoking
factors is the most important [12, 20]. Thrombosis fol-
lowing a major provocation, such as major surgery in the
preceding 3 months, carries a short term relative risk of
recurrence of 0.5 or less compared to the absence of an
identifiable provocation [20]. A large prospective registry
offered patients with VTE the opportunity to be screened
for hereditary thrombophilia. The risk of recurrence fol-
lowing an episode of provoked VTE was very low, and
recurrence rates did not differ among those with or without
a hereditary thrombophilia [35]. A large case–control study
and another prospective registry yielded similar results [16,
22]. Therefore, the risk:benefit balance favoring time-lim-
ited anticoagulation remains the same, regardless of the
presence of a thrombophilia. There is the potential for
patient harm if thrombophilia testing is performed after a
provoked VTE event, as healthcare providers may over-
estimate the risk of recurrence and prescribe extended
duration anticoagulation, subjecting patients to the unnec-
essary risk of bleeding [36, 37]. Other published guidelines
broadly agree that thrombophilia testing does not assist
with clinical decision making in cases of provoked VTE
and should not be performed [21, 25, 38, 39]. The Amer-
ican Society of Hematology (ASH) and the Society for
Vascular Medicine (SVM) recommended against testing in
such cases in their Choosing Wisely initiatives [36, 37].
Guidance Statement Do not perform thrombophilia
testing following an episode of provoked VTE.
Remark
A positive thrombophilia evaluation is not a sufficient basis
to offer extended anticoagulation following an episode of
provoked VTE.
Secondary prevention following unprovoked VTE
(2) Should thrombophilia testing be performed to help
determine duration of anticoagulation following
unprovoked VTE?
The absolute risk for recurrent VTE among patients with
unprovoked thrombosis is higher than among those with
provoked VTE, with 5-year risk approaching 30 % unless
extended-duration anticoagulant therapy is provided [20,
40]. Current guidelines from the American College of
Chest Physicians (ACCP) recommend extended duration
anticoagulation (anticoagulation with no planned stop date)
after unprovoked VTE unless the risk of bleeding is high or
this is contrary to the patient’s values and preferences [20].
However, anticoagulant medications confer an increased
risk of major bleeding, inconvenience to patients, and not
all patients will go on to develop recurrent thrombosis.
Therefore it would be desirable to offer extended antico-
agulation only to those who would benefit from it.
Thrombophilia testing has been suggested as a means to
identify these patients. However, a large registry did not
demonstrate a difference in rates of recurrent VTE in
patients who were tested for thrombophilia versus those
who were not, although the number of patients with AT,
PC, PS deficiencies or compound heterozygosity for FVL/
PGM was limited [35]. Several prospective registries and
case–control studies revealed clinically insignificant dif-
ferences in the VTE recurrence rates for those with or
without a hereditary thrombophilia [16, 22, 41, 42]. Some
thrombophilias, including APS, confer a higher risk of
recurrence than others (Table 2) and support the decision
Table 1 Guidance questions to be considered
Secondary prevention following provoked VTE
Should thrombophilia testing be performed to help determine duration of anticoagulation following provoked VTE?
Secondary prevention following unprovoked VTE
Should thrombophilia testing be performed to help determine duration of anticoagulation following unprovoked VTE?
Primary prevention in relatives of VTE patients
Should family members of patients with VTE or hereditary thrombophilia undergo thrombophilia testing?
Primary prevention in female relatives of VTE patients considering estrogen
Should female relatives of patients with VTE or hereditary thrombophilia who are considering using estrogen-containing medications be
tested for thrombophilia?
Primary prevention in female relatives of VTE patients who are contemplating pregnancy
Should female relatives of patients with VTE or hereditary thrombophilia who are contemplating pregnancy be tested for thrombophilia?
Timing of thrombophilia assessment
When thrombophilia testing is performed, at what point in the patient’s care should this be done?
156 S. M. Stevens et al.
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for extended anticoagulation. However, if a patient will
remain on indefinite anticoagulation based on the known
recurrence rate for unprovoked VTE, then thrombophilia
testing may not add additional utility. Therefore, the value
of testing is likely limited to patients who would stop
anticoagulants unless they are at even higher risk of
recurrence than the initial unprovoked event would predict.
There are also potential risks to thrombophilia testing after
unprovoked VTE. Negative testing for thrombophilia may
falsely reassure clinicians that the risk of recurrent VTE is
low after an unprovoked VTE, leading to cessation of
anticoagulation in patients at high risk for recurrence [43].
Conversely, finding a thrombophilia in a patient at high
bleeding risk may lead to continued anticoagulation, due to
an overestimation of the risk conferred by the condition.
Other published guidelines vary regarding thrombophilia
testing after unprovoked VTE [15, 38]. The National
Institute for Health and Clinical Excellence (NICE)
guidelines discourage testing for FVL and PGM, and
suggest selective testing for other conditions [21]. The
ACCP guideline lists thrombophilias among factors which
‘‘…predict risk of recurrence, but not strongly or consis-
tently enough to influence recommendations on duration of
therapy’’ [20]. Several risk prediction models (which do
not include thrombophilia testing) have been proposed to
help inform decisions regarding duration of anticoagulation
after unprovoked VTE; though some were derived in
populations which intentionally excluded patients with
known deficiency of PS, PC, AT and with APS [8, 44, 45].
As direct acting oral anticoagulants (DOACs) may confer a
lower risk of bleeding than warfarin during extended
therapy, the barriers to extended anticoagulation may be
lessened, perhaps further decreasing the utility of throm-
bophilia status to inform clinical decisions. Other factors,
such as the degree of post-thrombotic symptoms, D dimer
levels after a minimum of 3 months of anticoagulant
therapy, and residual vein thrombosis may also modify the
risk of recurrence [46–48].
Guidance Statement Do not perform thrombophilia
testing in patients following an episode of unprovoked
VTE.
Table 2 Prevalence and thrombosis risk for selected thrombophilias
Thrombophilia Prevalence Relative (absolute
annualized) risk of
Initial VTEa
Relative
risk of
recurrent
VTE
Relative (absolute
annualized) risk of
initial VTE, OCP
usersa,b
Relative (absolute
annualized) risk of
initial VTE, HRT
usersa,b,c
Relative (absolute)
risk of initial VTE,
pregnancya
FVL
Heterozygous
2–7 % 3.48–5.51
(0.05-0.2 %)
1.1–1.8 2.47–15.04
(0.1–0.6 %)
1.4–13.16 (1.6–5.97 %) 8.3
(0.8–4.6 %)
FVL
Homozygous
0.06–0.25 % 6.79–19.29
(0.8 %)
1.8 Uncertain Uncertain 34.4
(1.4–25.8 %)
PGM
Heterozygous
1–2 % 2.25–3.48
(0.13 %)
0.7–2.3 3.60–8.63 (2.85 %) 6.8
(0.3–5.6 %)
PGM
Homozygous
Rare 2.19–20.72 Uncertain Uncertain Uncertain 26
(0.2–78.3 %)
Compound
FVL & PGM
Heterozygosity
0.1 % 1.13–5.04
(0.42 %)
2.7 3.79–76.47
(0.17 %)
Uncertain (4 %)
PC deficiency 0.2–0.5 % 10
(0.4–2.3 %)
1.8 1.7–23.9
(1.7–7.1 %)
(2.96 %) 4.8
(0.4–8.9 %)
PS deficiency 0.1–0.7 % 9.6
(0.7–3.2 %)
1.0 1.4–17.1
(1.3–2.4 %)
(2.3 %) 3.2
(0.2–14.7 %)
AT deficiency 0.02 % 10–30
(1.2–4.4 %)
2.6 1.4–115.8
(2.5–5.1 %)
(5.73 %) 4.7
(0.08–15.8 %)
APS 2 % 7 1.5–6.8 0.3–3.1 (1.05–2.63 %) 15.8
OCP oral contraceptive pill (containing estrogen), HRT hormone replacement therapy (containing estrogen), VTE venous thromboembolism,
FVL factor V Leiden, PGM prothrombin Gene G20210A, PC protein C, PS protein S, AT antithrombin, APS antiphospholipid syndrome
a Data for are taken from several sources; absolute differences may therefore differ from calculations based on prevalence and relative risk [16,
17, 23, 32, 38, 50, 56, 62, 75–79]
b Relative risks are compared to non-users without thrombophilia
c With the exception of heterozygous FVL, estimates are based on modeling rather than epidemiologic studies
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Limits/exceptions
If a patient with unprovoked VTE and low bleeding risk is
planning to stop anticoagulation, test for thrombophilia
(Table 2) if test results would change this decision.
Remark
A negative thrombophilia evaluation is not a sufficient
basis to stop anticoagulants following an episode of
unprovoked VTE in a patient with low bleeding risk and
willingness to continue therapy.
Remark
Heterozygosity for FVL or PGM does not increase the
predicted risk of recurrence after unprovoked VTE to a
clinically significant degree.
See Chapter 3, ‘‘Guidance for the treatment of DVT and
PE’’ for guidance on determining duration of anticoagulant
therapy following unprovoked VTE.
Primary prevention in relatives of VTE patients
(3) Should family members of patients with VTE or
hereditary thrombophilia undergo thrombophilia
testing?
An additional rationale for hereditary thrombophilia
testing of patients with VTE is to identify conditions which
can lead to screening of asymptomatic family members.
Except for temporary prophylaxis during certain high risk
situations, anticoagulation for primary prevention of
thrombosis is not advocated regardless of the genetic defect
because the risk of bleeding may be higher than the
absolute risk of a first thrombotic event [19, 49–51].
However, it is argued that people who know their genotype
may be more likely to use preventive strategies in situa-
tions where the risk of thrombosis is elevated, such as
during hospitalization, following major surgery, and during
long distance travel. A large screening study of family
members of VTE patients revealed that asymptomatic
carriers of a hereditary thrombophilic defect were at excess
risk of thrombosis, with risks varying by disorder [52].
However, a family history of thrombosis alone carries an
increased risk, even in the absence of an identifiable
thrombophilia [43, 53–55]. Therefore, negative throm-
bophilia screening does not equate to normal VTE risk.
The impact of family screening on behavior was explored
in a cohort of 382 first degree family members of patients
with VTE and hereditary thrombophilia, who were tested
and followed over about 9 years [32]. Twice as many
thrombophilia carriers used prophylaxis in risk situations.
The rate of provoked VTE was higher in the group with
thrombophilia (0.58 %/year in those with hereditary
thrombophilia; 0.24 %/year in those without) although this
difference did not reach statistical significance (p = 0.08).
This study suggested a potential harm from screening, as it
demonstrated that family members who tested negative for
a thrombophilic defect were less likely to use prophylaxis.
Published guidelines vary substantially in regard to utility
of family screening [21, 25, 38, 39].
Guidance Statement Do not test for thrombophilia in
asymptomatic family members of patients with VTE or
hereditary thrombophilia.
Remark
As a family history of VTE confers an excess risk of
thrombosis, relatives should be counseled regarding use of
prophylaxis in high risk situations.
Primary prevention in female relatives of VTE patients
considering estrogen
(4) Should female relatives of patients with VTE or
hereditary thrombophilia who are considering using
estrogen-containing medications be tested for
thrombophilia?
Thrombophilias act synergistically with the pro-throm-
botic effects of estrogen-containing medications [19].
Therefore, identification of a hereditary thrombophilia by
family testing could result in choice of an alternate method
of contraception, or foregoing hormone replacement ther-
apy (HRT), thus avoiding the associated risk of thrombosis.
While the presence of thrombophilia significantly increases
the relative risk of a thrombotic event during use of an
estrogen-containing medication, the absolute risk remains
low (Table 2). This is especially true for oral contracep-
tives (OCPs), which are generally used by younger women
with a very low baseline risk for VTE. Studies focused on
testing for thrombophilia in the general female population
have suggested little utility and lack of cost-effectiveness.
For example, an economic modeling study calculated that
more 10,000 women would have to be screened for FVL,
and 500 women with the condition would have to avoid
OCPs in order to prevent one thrombotic event [56]. Over
92,000 FVL carriers would have to be identified and avoid
OCPs to prevent one fatal pulmonary embolism (PE), at a
cost of over $300 million [57]. Testing only patients with a
family history would likely increase test yield and improve
cost-effectiveness [56]. However, family history of VTE in
one or more first degree relatives predicts an elevated risk
of estrogen-associated VTE, regardless of whether throm-
bophilia is present [25, 53, 58]. Therefore it is possible that
women with negative tests could be falsely reassured, and
use estrogen in spite of an increased thrombosis risk. Other
published guidelines vary significantly regarding family
screening for the purposes of primary prevention in women
contemplating estrogens. The NICE guidelines recommend
against screening [21]. Medication package inserts contain
158 S. M. Stevens et al.
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precautions regarding estrogen-containing contraceptives
in women with a family history of VTE. Intrauterine
devices, including those which elute progestin, are a con-
traceptive option that does not increase the risk for
thrombosis [31]. While HRT prescriptions have declined
based on an unfavorable balance of risks and benefits [59],
women with a family history of VTE who strongly desire
HRT may mitigate VTE risk with use of a transdermal
preparation [60].
Guidance Statement Do not test for thrombophilia in
asymptomatic family members of patients with VTE or
hereditary thrombophilia who are contemplating use of
estrogen.
Limits/exceptions
If a woman contemplating estrogen use has a first-degree
relative with VTE and a known hereditary thrombophilia
(Table 2), test for that thrombophilia if the result would
change the decision to use estrogen.
Remark
Family history of VTE in a first degree relative predicts an
excess risk of thrombosis with estrogen use, even when
thrombophilia testing is negative.
Primary prevention in female relatives of VTE patients who
are contemplating pregnancy
(5) Should female relatives of patients with VTE or
hereditary thrombophilia who are contemplating
pregnancy be tested for thrombophilia?
Pregnancy is a period of particularly high risk for
thrombosis, causing a relative risk increase of 5–10 times
baseline [61]. The presence of a thrombophilic defect
amplifies this risk several-fold further (Table 2). Throm-
bophilia screening, if performed, would be most applicable
to the setting of primary prevention, as women with a prior
VTE that was unprovoked, or provoked by pregnancy or an
OCP, merit prophylaxis regardless of thrombophilia status
[25, 62]. A personal history of a prior VTE provoked by
surgery or trauma does not significantly increase the risk of
VTE during pregnancy; and no special prophylaxis mea-
sures are indicated ante-partum [25, 62–64]. Pregnant
patients with a first degree family member who has had
VTE do not appear to have an excess risk of thrombosis in
the absence of thrombophilia; therefore testing may be
more likely to distinguish women at low or higher throm-
bosis risk [65, 66]. Screening of unselected pregnant
women was not found to be cost-effective in a modeling
analysis despite the assumption that all women who tested
positive would use both antenatal and post-partum pro-
phylaxis [19]. However, restricting testing to women with a
first degree family member with VTE improved cost-
effectiveness. A recent multinational prospective, ran-
domized, open-label trial compared prophylaxis with dal-
teparin versus no prophylaxis in 289 pregnant women with
thrombophilia who were at increased risk of placenta-me-
diated pregnancy complications, VTE, or both. Antepartum
prophylactic dalteparin did not reduce the occurrence of
VTE, pregnancy loss, or placenta-mediated pregnancy
complications, but increased minor bleeding. All partici-
pants received post-partum prophylaxis with dalteparin
[67]. Systematic reviews have concluded that the evidence
supporting management decisions for pregnant patients
with FVL or PGM is low [68], and that practitioners are
often uncertain how to best manage these patients [27].
There are potential harms to testing. As prophylaxis is
generally recommended only to women who harbor less
common thrombophilias (see Chapter 6) [25, 62, 63], a
large number of women must be screened to detect each
case, resulting in significant expense [19]. Also, as
homozygosity for FVL is one of the higher-risk conditions
in pregnancy, screening will identify many heterozygotes
in order to detect the few homozygotes of interest. The
heterozygotes may experience worry, emotional distress or
challenges with insurability [28–30], while gaining little or
no utility from the information obtained. Other published
guidelines vary in suggesting broad [15] or selective [25,
63] screening of relatives of patients with VTE who are
contemplating pregnancy; and several guidelines advocate
prophylaxis of pregnant women in the presence of certain
thrombophilias [24, 62, 63, 69–71]; though the evidence
underlying these recommendations has been questioned
[68].
Guidance Statement Do not test for thrombophilia in
asymptomatic family members of patients with VTE or
hereditary thrombophilia who are contemplating
pregnancy.
Limits/exceptions
If a woman contemplating pregnancy has a first-degree
relative with VTE and a known hereditary thrombophilia
(Table 2), test for that thrombophilia if the result would
change VTE prophylaxis decisions.
Remark
Women with a personal history of unprovoked, estrogen-
associated or pregnancy associated VTE already carry an
indication for prophylaxis, and are unlikely to benefit from
thrombophilia testing.
Remark
Women with multiple family members affected by VTE
are more likely to carry a higher risk thrombophilia such as
AT deficiency which may impact prophylaxis decisions.
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Table 3 Summary of guidance statements
Question Guidance statement
Secondary prevention following provoked VTE
Should thrombophilia testing be performed to help determine
duration of anticoagulation following provoked VTE?
Do not perform thrombophilia testing following an episode of
provoked VTE.
Remark A positive thrombophilia evaluation is not a sufficient basis to
offer extended anticoagulation following an episode of provoked
VTE.
Secondary prevention following unprovoked VTE
Should thrombophilia testing be performed to help determine
duration of anticoagulation following unprovoked VTE?
Do not perform thrombophilia testing in patients following an episode
of unprovoked VTE.
Limits/exceptions If a patient with unprovoked VTE and low bleeding
risk is planning to stop anticoagulation, test for thrombophilia
(Table 2) if test results would change this decision.
Remark A negative thrombophilia evaluation is not a sufficient basis to
stop anticoagulants following an episode of unprovoked VTE in a
patient with low bleeding risk and willingness to continue therapy.
Remark Heterozygosity for FVL or PGM does not increase the
predicted risk of recurrence after unprovoked VTE to a clinically
significant degree.
See Chapter 3, ‘‘Guidance for the treatment of DVT and PE’’ for
guidance on determining duration of anticoagulant therapy following
unprovoked VTE.
Primary prevention in relatives of VTE patients
Should family members of patients with VTE or hereditary
thrombophilia undergo thrombophilia testing?
Do not test for thrombophilia in asymptomatic family members of
patients with VTE or hereditary thrombophilia.
Remark As a family history of VTE confers an excess risk of
thrombosis, relatives should be counseled regarding use of
prophylaxis in high risk situations.
Primary prevention in female relatives of VTE patients considering estrogen
Should female relatives of patients with VTE or hereditary
thrombophilia who are considering using estrogen-containing
medications be tested for thrombophilia?
Do not test for thrombophilia in asymptomatic family members of
patients with VTE or hereditary thrombophilia who are
contemplating use of estrogen.
Limits/exceptions If a woman contemplating estrogen use has a first-
degree relative with VTE and a known hereditary thrombophilia
(Table 2), test for that thrombophilia if the result would change the
decision to use estrogen.
Remark Family history of VTE in a first degree relative predicts an
excess risk of thrombosis with estrogen use, even when
thrombophilia testing is negative.
Primary prevention in female relatives of VTE patients who are contemplating pregnancy
Should female relatives of patients with VTE or hereditary
thrombophilia who are contemplating pregnancy be tested for
thrombophilia?
Do not test for thrombophilia in asymptomatic family members of
patients with VTE or hereditary thrombophilia who are
contemplating pregnancy.
Limits/exceptions If a woman contemplating pregnancy has a first-
degree relative with VTE and a known hereditary thrombophilia
(Table 2), test for that thrombophilia if the result would change VTE
prophylaxis decisions.
Remark Women with a personal history of unprovoked, estrogen-
associated or pregnancy associated VTE already carry an indication
for prophylaxis, and are unlikely to benefit from thrombophilia
testing.
Remark Women with multiple family members affected by VTE are
more likely to carry a higher risk thrombophilia such as AT
deficiency which may impact prophylaxis decisions.
See Chapter 6, ‘‘Guidance for the treatment of obstetric-associated
VTE’’ for regimens recommended for prophylaxis based on history
and thrombophilia status.
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See Chapter 6, ‘‘Guidance for the treatment of obstetric-
associated VTE’’ for regimens recommended for prophy-
laxis based on history and thrombophilia status.
Timing of thrombophilia assessment
(6) When thrombophilia testing is performed, at what
point in the patient’s care should this be done?
Genotype-based tests (such as those for FVL and PGM)
and antibody titers (for cardiolipin and beta-2 glycoprotein
I) can be performed accurately at any point in the care of a
patient. Certain assays for lupus anticoagulants can be
performed in the presence of heparins but others may
return a false-positive result. A clinician contemplating this
test should verify the assay used by the local laboratory
before performing the test in the setting of therapy with
heparin or low-molecular weight heparin. The remaining
thrombophilia tests are influenced by the presence of acute
thrombosis or anticoagulant therapy. Therefore, it is best to
avoid testing for these thrombophilias in the setting of an
acute VTE or while a patient is on an anticoagulant [31]. In
the patient with VTE in whom thrombophilia testing has
been chosen (see above), either deferring testing until
anticoagulation has been stopped, or a two-stage approach
is reasonable. In the two-stage approach, tests for throm-
bophilia that can be reliably done on anticoagulation (FVL,
PGM, cardiolipin and beta-2 Glycoprotein-I antibodies) are
performed before stopping anticoagulation. If these tests
are normal, anticoagulation is discontinued and the
remaining thrombophilia tests (lupus anticoagulant, PC, PS
and AT) are performed. A final decision on disposition of
anticoagulation can then be made on the basis of results.
The time that anticoagulation must be interrupted before
testing can take place is controversial, and may vary
according to the anticoagulant being used [25, 26, 72]. One
approach is to perform testing following a 2–4-week period
off anticoagulation, which would match the common tim-
ing for D-dimer assessment if this is also being performed
to assist in decision-making [46]. In the primary prevention
setting, it is important to note that pregnancy strongly
influences PS activity. It is unclear what PS activity value
is diagnostic of deficiency in the pregnant patient, but
thresholds have been suggested [24]. When testing is
chosen (see above), testing prior to pregnancy is preferred
[24]. Regardless of when tested, PS deficiency is difficult
to diagnose, and clinicians should be familiar with the
limitations of different assays, and consider seeking expert
consultation to confirm this diagnosis [73]. It is important
to note that the results of thrombophilia tests are frequently
misinterpreted by physicians [26] so correct timing of
testing and careful interpretation are essential [31, 74].
Guidance Statement
(1) Do not perform thrombophilia testing at the time of
VTE diagnosis or during the initial 3-month course
of anticoagulant therapy.
(2) When testing for thrombophilias following VTE, use
either a 2-stage testing approach (see above) or
perform testing after a minimum of 3 months of
anticoagulant therapy has been completed, and
anticoagulants have been held.
Remark
Pregnancy, sex and estrogen use reduce the levels of
Protein S. Use of sex specific reference intervals,
and testing prior to pregnancy or while not receiving
estrogen preparations is preferred.
Conclusion
Thrombophilia testing is performed far more frequently
than can be justified based on available evidence; the
majority of such testing is not of benefit to the patient and
may be harmful. Thrombophilia testing should not be
performed in patients with VTE following a major provo-
cation as extended anticoagulation is not indicated in these
cases. Patients with unprovoked VTE are at sufficiently
Table 3 continued
Question Guidance statement
Timing of thrombophilia assessment
When thrombophilia testing is performed, at what point in the
patient’s care should this be done?
Do not perform thrombophilia testing at the time of VTE diagnosis or
during the initial 3-month course of anticoagulant therapy.
When testing for thrombophilias following VTE, use either a 2-stage
testing approach (see text) or perform testing after a minimum of
3 months of anticoagulant therapy has been completed, and
anticoagulants have been held.
Remark Pregnancy, sex and estrogen use reduce the levels of Protein S.
Use of sex specific reference intervals, and testing prior to pregnancy
or while not receiving estrogen preparations is preferred.
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high risk of recurrent thrombosis that anticoagulation
should be continued regardless of thrombophilia status, as
long as bleeding risk is not high and treatment is consistent
with the patient’s values and preferences. Testing may
benefit select patients who would otherwise stop antico-
agulation. Thrombophilia testing is not indicated in most
family members of patients with VTE, as appropriate
decisions regarding use of prophylaxis in high-risk situa-
tions and choice of contraceptive methods can be made on
the basis of family history alone. Testing may be consid-
ered in female family members of patients with VTE and a
known hereditary thrombophilia if results will influence
choices regarding estrogen use or prophylaxis in the con-
text of pregnancy. Table 3 summarizes these guidance
statements.
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